The Immune Assessment of PD-1 Antibody Therapy in Tumor

RecruitingOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

November 13, 2027

Study Completion Date

November 13, 2030

Conditions

Efficacy, TeamAdverse Event

Interventions

DRUG

PD-1 Inhibitors

Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice

Trial Locations (1)

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Quanli Gao

OTHER_GOV